Cargando…

The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer

PURPOSE: Chemotherapy-induced diarrhoea (CID) is a common, but often underreported problem in patients with breast cancer that has a profound effect on quality of life. It is best measured from a patient’s perspective, but tools are limited. The aim of this study was to develop and evaluate the Diar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harder, Helena, Shilling, Valerie M., May, Shirley F., Cella, David, Schmid, Peter, Fallowfield, Lesley J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497672/ https://www.ncbi.nlm.nih.gov/pubmed/32720113 http://dx.doi.org/10.1007/s10549-020-05798-w

Ejemplares similares

Using patient perspectives to inform communication training materials for health care professionals discussing BRCA mutation testing
por: Shilling, Valerie, et al.
Publicado: (2020)

Development and validation of the patient roles and responsibilities scale in cancer patients
por: Shilling, Valerie, et al.
Publicado: (2018)

Development and validation of the caregiver roles and responsibilities scale in cancer caregivers
por: Shilling, Valerie, et al.
Publicado: (2019)

Talking about risk in the context of genomic tests (TARGET): development and evaluation of an educational program for clinicians
por: Fallowfield, L., et al.
Publicado: (2019)

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
por: O’Shaughnessy, Joyce, et al.
Publicado: (2022)

A systematic review of communication interventions to help healthcare professionals discuss genetic testing for breast cancer
por: Starkings, Rachel, et al.
Publicado: (2020)

Chemotherapy use near the end-of-life in patients with metastatic breast cancer
por: Edman Kessler, Luisa, et al.
Publicado: (2020)

Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer
por: Souwer, E. T. D., et al.
Publicado: (2023)

HER2-targeted therapy influences CTC status in metastatic breast cancer
por: Deutsch, Thomas M., et al.
Publicado: (2020)

Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer
por: Pezo, Rossanna C., et al.
Publicado: (2017)

The value of mammography in women with focal breast complaints in addition to initial targeted ultrasound
por: Appelman, L., et al.
Publicado: (2020)

Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer
por: Vriens, B. E. P. J., et al.
Publicado: (2017)

Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer
por: Chalasani, Pavani, et al.
Publicado: (2021)

An online review of informational sources for advanced or high-risk cutaneous squamous cell carcinoma
por: Starkings, Rachel, et al.
Publicado: (2021)

The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II–III and metastatic breast cancers
por: Anderson, Karen S., et al.
Publicado: (2022)

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
por: De Boer, Richard H., et al.
Publicado: (2012)

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
por: Twelves, Chris, et al.
Publicado: (2014)

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
por: Tolaney, Sara M., et al.
Publicado: (2016)

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
por: Sachdev, Jasgit C., et al.
Publicado: (2020)

Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study
por: Boman, Caroline, et al.
Publicado: (2022)

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
por: Ma, Cynthia X., et al.
Publicado: (2012)

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
por: Haddad, Tufia C., et al.
Publicado: (2017)

A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns
por: Tzikas, Anna-Karin, et al.
Publicado: (2020)

Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer
por: Walter, Vincent, et al.
Publicado: (2020)

Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer
por: Coe, Faye, et al.
Publicado: (2021)

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
por: Rugo, Hope S., et al.
Publicado: (2020)

Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen
por: Bychkovsky, Brittany, et al.
Publicado: (2022)

nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis
por: O’Shaughnessy, Joyce, et al.
Publicado: (2013)

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
por: Yu, Y. F., et al.
Publicado: (2017)

Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer—results of an exploratory case–control study
por: Krajnak, S., et al.
Publicado: (2020)

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
por: Wardley, Andrew, et al.
Publicado: (2021)

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
por: Cazzaniga, M. E., et al.
Publicado: (2021)

Patient-reported outcome measures for cancer caregivers: a systematic review
por: Shilling, Valerie, et al.
Publicado: (2016)

The pervasive nature of uncertainty—a qualitative study of patients with advanced cancer and their informal caregivers
por: Shilling, Valerie, et al.
Publicado: (2017)

Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer
por: Li, Huiping, et al.
Publicado: (2021)

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
por: Schuler, Martin, et al.
Publicado: (2012)

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy
por: Vahdat, Linda T., et al.
Publicado: (2013)

Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance
por: Inoue, Kenichi, et al.
Publicado: (2016)

Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
por: Xu, Binghe, et al.
Publicado: (2022)

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer
por: Modi, Shanu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_eqng25lfo0ehfegrk7fmdkol3v